Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
PLx Pharma initiated with an Outperform at Oppenheimer » 08:10
04/09/21
04/09
08:10
04/09/21
08:10
PLXP

PLx Pharma

$8.96 /

-0.075 (-0.83%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell initiated coverage of PLx Pharma with an Outperform rating and $20 price target. Led by a commercially savvy team and now armed with its first approval, PLx is well-positioned to compete for consumer, provider, and channel attention in the ~$10B U.S. secondary cardiovascular prevention retail market, Gershell tells investors in a research note.

ShowHide Related Items >><<
PLXP PLx Pharma
$8.96 /

-0.075 (-0.83%)

PLXP PLx Pharma
$8.96 /

-0.075 (-0.83%)

04/09/21 Oppenheimer
PLx Pharma initiated with an Outperform at Oppenheimer
03/01/21 JMP Securities
PLx Pharma price target raised to $12 from $9 at JMP Securities
05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
PLXP PLx Pharma
$8.96 /

-0.075 (-0.83%)

  • 03
    Mar
PLXP PLx Pharma
$8.96 /

-0.075 (-0.83%)

Initiation
PLx Pharma initiated with an Outperform at Oppenheimer » 06:47
04/09/21
04/09
06:47
04/09/21
06:47
PLXP

PLx Pharma

$8.96 /

-0.075 (-0.83%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell initiated coverage of PLx Pharma with an Outperform rating and $20 price target.

ShowHide Related Items >><<
PLXP PLx Pharma
$8.96 /

-0.075 (-0.83%)

PLXP PLx Pharma
$8.96 /

-0.075 (-0.83%)

03/01/21 JMP Securities
PLx Pharma price target raised to $12 from $9 at JMP Securities
05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
PLXP PLx Pharma
$8.96 /

-0.075 (-0.83%)

  • 03
    Mar
PLXP PLx Pharma
$8.96 /

-0.075 (-0.83%)

Over a week ago
Options
new option listings on March 17th » 08:30
03/17/21
03/17
08:30
03/17/21
08:30
ABCL

AbCellera

$37.78 /

+0.18 (+0.48%)

, AFIN

American Finance Trust

$10.34 /

-0.12 (-1.15%)

, AONE

One

$12.57 /

-0.36 (-2.78%)

, CCCC

C4 Therapeutics

$43.90 /

-0.665 (-1.49%)

, CPNG

Coupang

$47.03 /

-3.42 (-6.78%)

, DEN

Denbury

$41.37 /

-1.74 (-4.04%)

, DRIO

DarioHealth

$19.50 /

-0.355 (-1.79%)

, ELVT

Elevate Credit

$4.49 /

+0.03 (+0.67%)

, ESTE

Earthstone Energy

$8.61 /

+0.06 (+0.70%)

, FLL

Full House Resorts

$8.32 /

-0.61 (-6.83%)

, FMTX

Forma Therapeutics

$34.63 /

-0.25 (-0.72%)

, GBIO

Generation Bio

$34.04 /

-0.99 (-2.83%)

, HTOO

Fusion Fuel

$15.09 /

-1.71 (-10.18%)

, IRIX

Iridex

$7.56 /

+0.06 (+0.80%)

, JMP

JMP Group

$5.69 /

-0.08 (-1.39%)

, LGHL

Lion Group

$3.50 /

-0.5 (-12.50%)

, LTRN

Lantern Pharma

$21.26 /

+2.22 (+11.66%)

, NRIX

Nurix Therapeutics

$45.58 /

+1.55 (+3.52%)

, PCVX

Vaxcyte

$26.76 /

-0.26 (-0.96%)

, PLXP

PLx Pharma

$9.16 /

+0.69 (+8.15%)

, PMVP

PMV Pharmaceuticals

$39.87 /

-0.03 (-0.08%)

, RSVA

Rodgers Silicon Valley Acquisition

$15.84 /

-0.02 (-0.13%)

, SY

So-Young

$12.54 /

+0.19 (+1.54%)

, USIO

Usio

$5.53 /

-0.49 (-8.14%)

, WYY

WidePoint

$11.77 /

+0.36 (+3.16%)

New option listings for…

New option listings for March 17th include AbCellera Biologics Inc (ABCL), American Financial Trust Inc (Class A Stock) (AFIN), one (Class A Stock) (AONE), C4 Therapeutics Inc (CCCC), Coupang Inc (Class A Stock) (CPNG), Denbury Inc (DEN), DarioHealth (DRIO), Elevate (ELVT), Earthstone Energy (ESTE), Full House Resorts (FLL), Forma Therapeutics Holdings Inc (FMTX), Generation Bio Company (GBIO), Fusion Fuel Green PLC (Class A Stock) (HTOO), IRIDEX (IRIX), JMP Group (JMP), Lion Group Holding Ltd (ADS) (LGHL), Lantern Pharma Inc (LTRN), Nurix Therapeutics Inc (NRIX), Vaxcyte Inc (PCVX), PLx Pharma (PLXP), PMV Pharmaceuticals Inc (PMVP), Rodgers Silicon Valley Acquisition Corporation (RSVA), So Young International (SY), Usio Inc (USIO), and WidePoint (WYY).

ShowHide Related Items >><<
WYY WidePoint
$11.77 /

+0.36 (+3.16%)

USIO Usio
$5.53 /

-0.49 (-8.14%)

PMVP PMV Pharmaceuticals
$39.87 /

-0.03 (-0.08%)

PLXP PLx Pharma
$9.16 /

+0.69 (+8.15%)

PCVX Vaxcyte
$26.76 /

-0.26 (-0.96%)

NRIX Nurix Therapeutics
$45.58 /

+1.55 (+3.52%)

LTRN Lantern Pharma
$21.26 /

+2.22 (+11.66%)

LGHL Lion Group
$3.50 /

-0.5 (-12.50%)

JMP JMP Group
$5.69 /

-0.08 (-1.39%)

IRIX Iridex
$7.56 /

+0.06 (+0.80%)

HTOO Fusion Fuel
$15.09 /

-1.71 (-10.18%)

GBIO Generation Bio
$34.04 /

-0.99 (-2.83%)

FMTX Forma Therapeutics
$34.63 /

-0.25 (-0.72%)

FLL Full House Resorts
$8.32 /

-0.61 (-6.83%)

ESTE Earthstone Energy
$8.61 /

+0.06 (+0.70%)

ELVT Elevate Credit
$4.49 /

+0.03 (+0.67%)

DRIO DarioHealth
$19.50 /

-0.355 (-1.79%)

DEN Denbury
$41.37 /

-1.74 (-4.04%)

CPNG Coupang
$47.03 /

-3.42 (-6.78%)

CCCC C4 Therapeutics
$43.90 /

-0.665 (-1.49%)

AONE One
$12.57 /

-0.36 (-2.78%)

AFIN American Finance Trust
$10.34 /

-0.12 (-1.15%)

ABCL AbCellera
$37.78 /

+0.18 (+0.48%)

ABCL AbCellera
$37.78 /

+0.18 (+0.48%)

02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
01/26/21 Berenberg
Eli Lilly data 'incrementally positive' for AbCellera, says Berenberg
01/25/21 BMO Capital
AbCellera price target raised to $61 from $48 at BMO Capital
01/05/21
Fly Intel: Top five analyst initiations
AFIN American Finance Trust
$10.34 /

-0.12 (-1.15%)

03/01/21 B. Riley
American Finance Trust price target raised to $11 from $9 at B. Riley
11/09/20 B. Riley
American Finance Trust price target lowered to $9 from $10 at B. Riley Securities
03/26/20 B. Riley
American Finance Trust upgraded to Buy from Neutral at B. Riley FBR
AONE One
$12.57 /

-0.36 (-2.78%)

CCCC C4 Therapeutics
$43.90 /

-0.665 (-1.49%)

12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
10/28/20 UBS
C4 Therapeutics initiated with a Buy at UBS
10/27/20 Jefferies
C4 Therapeutics initiated with a Buy at Jefferies
CPNG Coupang
$47.03 /

-3.42 (-6.78%)

DEN Denbury
$41.37 /

-1.74 (-4.04%)

01/20/21 Roth Capital
Denbury initiated with a Buy at Roth Capital
09/22/20 Capital One
Denbury upgraded to Overweight from Underweight at Capital One
09/22/20 Capital One
Denbury upgraded to Overweight from Equalweight at Capital One
09/21/20 Alliance Global Partners
Alliance Global upgrades Evolution Petroleum on removed near-term risks
DRIO DarioHealth
$19.50 /

-0.355 (-1.79%)

02/01/21 Alliance Global Partners
DarioHealth downgraded to Neutral from Buy at Alliance Global Partners
08/17/20 Aegis
DarioHealth initiated with a Buy at Aegis
08/13/20 Craig-Hallum
DarioHealth price target raised to $17 from $8 at Craig-Hallum
06/22/20 ThinkEquity
DarioHealth initiated with a Buy at ThinkEquity
ELVT Elevate Credit
$4.49 /

+0.03 (+0.67%)

04/14/20 Maxim
LendingClub, Enova International, Elevate Credit cut to Hold at Maxim
04/14/20 Maxim
Elevate Credit downgraded to Hold from Buy at Maxim
ESTE Earthstone Energy
$8.61 /

+0.06 (+0.70%)

01/04/21 Northland
Earthstone Energy named a Top Pick for 2021 at Northland
12/16/20 Wells Fargo
Wells Fargo says Buy Marathon Oil, Sell Berry Petroleum
12/16/20 Wells Fargo
Earthstone Energy upgraded to Overweight from Equal Weight at Wells Fargo
09/02/20 Alliance Global Partners
Earthstone Energy assumed with a Buy at Alliance Global Partners
FLL Full House Resorts
$8.32 /

-0.61 (-6.83%)

03/09/21 Macquarie
Full House Resorts price target raised to $10 from $8 at Macquarie
02/18/21 Union Gaming
Full House Resorts initiated with a Buy at Union Gaming
02/05/21 Macquarie
Full House Resorts price target raised to $8 from $6 at Macquarie
12/02/20 Macquarie
Full House Resorts price target raised to $5 from $4.50 at Macquarie
FMTX Forma Therapeutics
$34.63 /

-0.25 (-0.72%)

02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/09/20 BMO Capital
Agios Pharmaceuticals price target lowered to $50 from $57 at BMO Capital
GBIO Generation Bio
$34.04 /

-0.99 (-2.83%)

02/23/21 William Blair
Generation Bio initiated with an Outperform at William Blair
02/23/21 William Blair
Generation Bio initiated with an Outperform at William Blair
02/18/21 Needham
Generation Bio initiated with a Buy at Needham
07/07/20 Cowen
Generation Bio initiated with an Outperform at Cowen
HTOO Fusion Fuel
$15.09 /

-1.71 (-10.18%)

IRIX Iridex
$7.56 /

+0.06 (+0.80%)

JMP JMP Group
$5.69 /

-0.08 (-1.39%)

02/22/21 Barrington
JMP Group price target raised to $7.50 from $3.50 at Barrington
LGHL Lion Group
$3.50 /

-0.5 (-12.50%)

LTRN Lantern Pharma
$21.26 /

+2.22 (+11.66%)

08/10/20 ThinkEquity
Lantern Pharma initiated with a Buy at ThinkEquity
07/28/20 Colliers
Drug 'rescuer' Lantern Pharma started at Buy at Colliers
07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
NRIX Nurix Therapeutics
$45.58 /

+1.55 (+3.52%)

02/17/21 Piper Sandler
Nurix Therapeutics price target raised to $60 from $40 at Piper Sandler
02/16/21 Piper Sandler
Nurix Therapeutics price target raised to $60 from $40 at Piper Sandler
01/29/21 JPMorgan
Nurix Therapeutics price target raised to $56 from $34 at JPMorgan
PCVX Vaxcyte
$26.76 /

-0.26 (-0.96%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
07/07/20
Fly Intel: Top five analyst initiations
07/07/20 BofA
Vaxcyte initiated with a Buy at BofA
07/07/20 Jefferies
Vaxcyte initiated with a Buy at Jefferies
PLXP PLx Pharma
$9.16 /

+0.69 (+8.15%)

03/01/21 JMP Securities
PLx Pharma price target raised to $12 from $9 at JMP Securities
05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
PMVP PMV Pharmaceuticals
$39.87 /

-0.03 (-0.08%)

10/20/20 Evercore ISI
PMV Pharmaceuticals initiated with an Outperform at Evercore ISI
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 Cowen
PMV Pharmaceuticals initiated with an Outperform at Cowen
RSVA Rodgers Silicon Valley Acquisition
$15.84 /

-0.02 (-0.13%)

03/11/21 Northland
Rodgers Silicon Valley Acquisition initiated with an Outperform at Northland
SY So-Young
$12.54 /

+0.19 (+1.54%)

04/23/20
Fly Intel: Top five analyst initiations
04/23/20 Deutsche Bank
So-Young initiated with a Buy, $16.20 target at Deutsche Bank
04/23/20 Deutsche Bank
So-Young initiated with a Buy at Deutsche Bank
03/25/20 86 Research
So-Young upgraded to Buy from Hold at 86 Research
USIO Usio
$5.53 /

-0.49 (-8.14%)

02/16/21 Alliance Global Partners
Usio shares 'over-bought' after 320% rally, says Alliance Global Partners
08/03/20 Alliance Global Partners
Alliance Global Partners downgrades Usio to Neutral, predicts 'weak' Q2 report
08/03/20 Alliance Global Partners
Usio downgraded to Neutral from Buy at Alliance Global Partners
05/07/20
Fly Intel: Top five analyst initiations
WYY WidePoint
$11.77 /

+0.36 (+3.16%)

12/01/20 B. Riley
WidePoint price target raised to $13 from $10 at B. Riley Securities
USIO Usio
$5.53 /

-0.49 (-8.14%)

PMVP PMV Pharmaceuticals
$39.87 /

-0.03 (-0.08%)

PLXP PLx Pharma
$9.16 /

+0.69 (+8.15%)

NRIX Nurix Therapeutics
$45.58 /

+1.55 (+3.52%)

LTRN Lantern Pharma
$21.26 /

+2.22 (+11.66%)

IRIX Iridex
$7.56 /

+0.06 (+0.80%)

GBIO Generation Bio
$34.04 /

-0.99 (-2.83%)

FMTX Forma Therapeutics
$34.63 /

-0.25 (-0.72%)

FLL Full House Resorts
$8.32 /

-0.61 (-6.83%)

ESTE Earthstone Energy
$8.61 /

+0.06 (+0.70%)

ELVT Elevate Credit
$4.49 /

+0.03 (+0.67%)

DRIO DarioHealth
$19.50 /

-0.355 (-1.79%)

  • 03
    Mar
  • 05
    Mar
  • 11
    Mar
  • 15
    Jan
  • 07
    Jan
  • 11
    Dec
  • 11
    Dec
  • 02
    Oct
  • 23
    Sep
  • 25
    Sep
  • 24
    Jul
  • 19
    Jun
  • 11
    Jun
  • 12
    Jun
  • 12
    Jun
CPNG Coupang
$47.03 /

-3.42 (-6.78%)

WYY WidePoint
$11.77 /

+0.36 (+3.16%)

USIO Usio
$5.53 /

-0.49 (-8.14%)

PMVP PMV Pharmaceuticals
$39.87 /

-0.03 (-0.08%)

IRIX Iridex
$7.56 /

+0.06 (+0.80%)

GBIO Generation Bio
$34.04 /

-0.99 (-2.83%)

FLL Full House Resorts
$8.32 /

-0.61 (-6.83%)

ELVT Elevate Credit
$4.49 /

+0.03 (+0.67%)

CPNG Coupang
$47.03 /

-3.42 (-6.78%)

CCCC C4 Therapeutics
$43.90 /

-0.665 (-1.49%)

ABCL AbCellera
$37.78 /

+0.18 (+0.48%)

SY So-Young
$12.54 /

+0.19 (+1.54%)

Earnings
PLx Pharma reports Q4 EPS (87c) with items, consensus (29c) » 06:56
03/12/21
03/12
06:56
03/12/21
06:56
PLXP

PLx Pharma

$7.94 /

+0.07 (+0.89%)

The fourth quarter of…

The fourth quarter of 2020 included a non-cash loss of $4.2M, or (44c) per share, related to the change in fair value of warrant liability and $0.5M, or (5c) per share, of Series A and Series B convertible preferred stock dividends.

ShowHide Related Items >><<
PLXP PLx Pharma
$7.94 /

+0.07 (+0.89%)

PLXP PLx Pharma
$7.94 /

+0.07 (+0.89%)

03/01/21 JMP Securities
PLx Pharma price target raised to $12 from $9 at JMP Securities
05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
  • 03
    Mar
Over a month ago
Syndicate
PLx Pharma 7.88M share Spot Secondary priced at $8.00 » 08:59
03/03/21
03/03
08:59
03/03/21
08:59
PLXP

PLx Pharma

$8.98 /

+0.31 (+3.58%)

The deal priced below the…

The deal priced below the last closing price of $9.14. Raymond James and Oppenheimer are acting as joint book running managers for the offering.

ShowHide Related Items >><<
PLXP PLx Pharma
$8.98 /

+0.31 (+3.58%)

PLXP PLx Pharma
$8.98 /

+0.31 (+3.58%)

03/01/21 JMP Securities
PLx Pharma price target raised to $12 from $9 at JMP Securities
05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
  • 03
    Mar
Syndicate
PLx Pharma files to sell common stock, no amount given » 16:06
03/02/21
03/02
16:06
03/02/21
16:06
PLXP

PLx Pharma

$8.71 /

+0.04 (+0.46%)

PLx intends to use the…

PLx intends to use the net proceeds from this offering for general corporate purposes. General corporate purposes may include additions to working capital and capital expenditures. Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. are acting as the joint book-running managers for the public offering.

ShowHide Related Items >><<
PLXP PLx Pharma
$8.71 /

+0.04 (+0.46%)

PLXP PLx Pharma
$8.71 /

+0.04 (+0.46%)

03/01/21 JMP Securities
PLx Pharma price target raised to $12 from $9 at JMP Securities
05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
Recommendations
PLx Pharma price target raised to $12 from $9 at JMP Securities » 11:29
03/01/21
03/01
11:29
03/01/21
11:29
PLXP

PLx Pharma

$9.40 /

+1.84 (+24.34%)

JMP Securities analyst…

JMP Securities analyst Jason Butler raised the firm's price target on PLx Pharma to $12 from $9 and keeps an Outperform rating on the shares after the company announced that the FDA has approved the sNDAs for both the 81mg and 325mg doses of Vazalore. He believes the company is well positioned for "a strong targeted launch" of its PLxGuard formulation of aspirin, the analyst tells investors following the approval news.

ShowHide Related Items >><<
PLXP PLx Pharma
$9.40 /

+1.84 (+24.34%)

PLXP PLx Pharma
$9.40 /

+1.84 (+24.34%)

05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
Hot Stocks
PLx Pharma receives FDA approval of sNDAs for VAZALORE 325 mg, 81 mg » 06:52
03/01/21
03/01
06:52
03/01/21
06:52
PLXP

PLx Pharma

$7.56 /

+0.2 (+2.72%)

PLx Pharma announced that…

PLx Pharma announced that the U.S. FDA approved supplemental new drug applications for its lead products, VAZALORE 325 mg and VAZALORE 81 mg, the first ever novel, liquid-filled aspirin capsule. "We are delighted that the FDA approved both sNDAs for VAZALORE, and we are eager to implement our commercial launch plans later this year," stated Natasha Giordano, President and CEO of PLx.

ShowHide Related Items >><<
PLXP PLx Pharma
$7.56 /

+0.2 (+2.72%)

PLXP PLx Pharma
$7.56 /

+0.2 (+2.72%)

05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
Over a quarter ago
Syndicate
PLx Pharma files to sell 9.99M shares of common stock for holders  17:18
12/21/20
12/21
17:18
12/21/20
17:18
PLXP

PLx Pharma

$6.52 /

+0.63 (+10.70%)

 
ShowHide Related Items >><<
PLXP PLx Pharma
$6.52 /

+0.63 (+10.70%)

PLXP PLx Pharma
$6.52 /

+0.63 (+10.70%)

05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
PLXP PLx Pharma
$6.52 /

+0.63 (+10.70%)

Hot Stocks
PLx Pharma submits sNDAs for Vazalore 325 and 81 mg to FDA » 16:08
11/16/20
11/16
16:08
11/16/20
16:08
PLXP

PLx Pharma

$4.57 /

+0.26 (+6.03%)

PLx Pharma announcedthat…

PLx Pharma announcedthat two chemistry and manufacturing control, CMC, supplemental New Drug Applications , one for VAZALORE 325 mg and one for VAZALORE 81 mg dose (referred to together as, were submitted to the U.S. Food and Drug Administrationin October for regulatory approval. The 325 mg sNDA provided information on a change in formulation and a new manufacturing site for the currently approved VAZALORE and also contains a bioequivalence clinical study report with the required data and analyses from the recently completed BE study. The submission for the 81 mg dose provided for a new product strength of VAZALORE and builds off the information in the original approved NDA and the recent sNDA submitted for VAZALORE 325 mg. The Company received acknowledgement letters from the FDA, officially confirming the receipt of the submissions and setting the estimated completion date for its reviews for VAZALORE 325 mg and VAZALORE 81 mg for the end of February 2021. If approved, the Company plans to bring both doses of VAZALORE to market in the third quarter of 2021. "We are delighted to have achieved this major milestone for the submissions of our two sNDAs to the FDA earlier than previously announced. This is a significant step for PLx and the millions of patients with vascular disease who can benefit from a novel aspirin therapy. We are highly confident our submissions are supported by strong and compelling data that FDA requires for CMC submissions and we look forward to their review," stated Natasha Giordano, President and Chief Executive Officer of PLx. "I'd also like to thank our teams and our partners for their extraordinary efforts preparing these filings and our shareholders for their support in advancing VAZALORE to regulatory review," concluded Giordano.

ShowHide Related Items >><<
PLXP PLx Pharma
$4.57 /

+0.26 (+6.03%)

PLXP PLx Pharma
$4.57 /

+0.26 (+6.03%)

05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
PLXP PLx Pharma
$4.57 /

+0.26 (+6.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.